Peter Schmid

1.7k total citations
49 papers, 1.1k citations indexed

About

Peter Schmid is a scholar working on Oncology, Ecology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Peter Schmid has authored 49 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 20 papers in Ecology and 19 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Peter Schmid's work include Fish Ecology and Management Studies (18 papers), Advanced Breast Cancer Therapies (14 papers) and Aquatic Invertebrate Ecology and Behavior (13 papers). Peter Schmid is often cited by papers focused on Fish Ecology and Management Studies (18 papers), Advanced Breast Cancer Therapies (14 papers) and Aquatic Invertebrate Ecology and Behavior (13 papers). Peter Schmid collaborates with scholars based in United Kingdom, United States and Spain. Peter Schmid's co-authors include J. M. Schmid‐Araya, Alan G. Hildrew, M. Tokeshi, Anne L. Robertson, Julie H. Winterbottom, Mutsunori Tokeshi, Javier Cortés, Alexander D. Huryn, David Atkinson and Joel E. Cohen and has published in prestigious journals such as Science, Journal of Clinical Oncology and Ecology.

In The Last Decade

Peter Schmid

45 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter Schmid United Kingdom	17	666	422	228	180	135	49	1.1k
Denis Roy Canada	20	647 1.0×	616 1.5×	254 1.1×	106 0.6×	99 0.7×	38	2.4k
Stephen D. Hurd United States	9	975 1.5×	422 1.0×	361 1.6×	274 1.5×	47 0.3×	11	1.8k
Daisuke Nakano Japan	20	542 0.8×	264 0.6×	141 0.6×	32 0.2×	42 0.3×	68	952
Brian J. Burke United States	23	749 1.1×	921 2.2×	60 0.3×	154 0.9×	30 0.2×	73	1.8k
Günter Köhler Germany	18	357 0.5×	511 1.2×	164 0.7×	38 0.2×	18 0.1×	87	1.6k
R Swain Australia	19	337 0.5×	133 0.3×	653 2.9×	69 0.4×	34 0.3×	79	2.0k
Philippe Riou France	24	341 0.5×	108 0.3×	266 1.2×	362 2.0×	235 1.7×	46	2.1k
Deborah R. Hart United States	24	800 1.2×	396 0.9×	58 0.3×	429 2.4×	539 4.0×	66	1.9k
Torsten J. Schulze Germany	18	273 0.4×	229 0.5×	225 1.0×	42 0.2×	64 0.5×	47	1.0k
Russell A. Wright United States	19	514 0.8×	796 1.9×	26 0.1×	77 0.4×	175 1.3×	56	1.1k

Countries citing papers authored by Peter Schmid

Since Specialization

Citations

This map shows the geographic impact of Peter Schmid's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Schmid with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Schmid more than expected).

Fields of papers citing papers by Peter Schmid

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Schmid. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Schmid. The network helps show where Peter Schmid may publish in the future.

Co-authorship network of co-authors of Peter Schmid

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Schmid. A scholar is included among the top collaborators of Peter Schmid based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Schmid. Peter Schmid is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jhaveri, Komal, Fabrice André, Erika Hamilton, et al.. (2025). Abstract P3-09-17: Trastuzumab deruxtecan (T-DXd) in combination with capecitabine or capivasertib in patients with HER2-low metastatic breast cancer: a Phase 1b, multicenter, open-label study (DESTINY-Breast08). Clinical Cancer Research. 31(12_Supplement). P3–9.

Graeser, Monika, Oleg Gluz, Peter Schmid, et al.. (2024). Multiomic factor analysis for pathologic complete response (pCR) after 12 weeks of pembrolizumab + trastuzumab + pertuzumab in HER2-enriched (HER2-E) early breast cancer (eBC) in the Keyriched-1 trial.. Journal of Clinical Oncology. 42(16_suppl). 590–590. 1 indexed citations

Harbeck, Nadia, Michael Braun, Oleg Gluz, et al.. (2024). Neoadjuvant dynamic marker-adjusted personalized therapy comparing trastuzumab-deruxtecan versus pacli-/docetaxel + carboplatin + trastuzumab + pertuzumab in HER2+ early breast cancer: WSG-ADAPT-HER2-IV.. Journal of Clinical Oncology. 42(16_suppl). TPS631–TPS631. 2 indexed citations

Schmid, Peter, et al.. (2024). Abstract PO1-19-10: Durvalumab + datopotamab deruxtecan in patients with PD-L1 positive advanced/metastatic triple-negative breast cancer: Arm 8 of the phase 1b/2, open label, platform BEGONIA study. Cancer Research. 84(9_Supplement). PO1–19. 1 indexed citations

Bardia, Aditya, Peter Schmid, Sara M. Tolaney, et al.. (2024). Abstract PO5-21-09: Clinical outcomes by age subgroups in the phase 3 TROPiCS-02 study of sacituzumab govitecan vs treatment of physician’s choice in HR+/HER2‒ metastatic breast cancer. Cancer Research. 84(9_Supplement). PO5–21. 3 indexed citations

Conté, Pierfranco, Maria Vittoria Dieci, Giancarlo Bisagni, et al.. (2024). A-BRAVE trial: A phase III randomized trial with avelumab in early triple-negative breast cancer with residual disease after neoadjuvant chemotherapy or at high risk after primary surgery and adjuvant chemotherapy.. Journal of Clinical Oncology. 42(17_suppl). LBA500–LBA500. 16 indexed citations

Bardia, Aditya, Frederik Marmé, Peter Schmid, et al.. (2024). Genomic alterations in DNA damage response (DDR) genes in HR+/HER2- metastatic breast cancer (mBC) and impact on clinical efficacy with sacituzumab govitecan (SG): Biomarker results from TROPICS-02 study.. Journal of Clinical Oncology. 42(16_suppl). 1075–1075. 2 indexed citations

Licata, Luca, Maria Vittoria Dieci, Carmine De Angelis, et al.. (2024). Navigating practical challenges in immunotherapy for metastatic triple negative breast cancer. Cancer Treatment Reviews. 128. 102762–102762. 6 indexed citations

Anders, Carey K., Sherene Loi, Erika Hamilton, et al.. (2024). NVTG-07 SAFETY, TOLERABILITY, AND ANTITUMOR ACTIVITY OF TRASTUZUMAB DERUXTECAN (T-DXD) IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER (MBC) AND ACTIVE BRAIN METASTASES (BMS) IN DESTINY-BREAST07 (DB-07). Neuro-Oncology Advances. 6(Supplement_1). i25–i25.

10.

Rugo, Hope S., Peter Schmid, Sara M. Tolaney, et al.. (2024). Health-related quality of life with sacituzumab govitecan in HR+/HER2− metastatic breast cancer in the phase III TROPiCS-02 trial. The Oncologist. 29(9). 768–779. 7 indexed citations

11.

Schmid, Peter, Sherene Loi, Luis de la Cruz‐Merino, et al.. (2024). 181O Interim analysis (IA) of the atezolizumab (atezo) + sacituzumab govitecan (SG) arm in patients (pts) with triple-negative breast cancer (TNBC) in MORPHEUS-pan BC: A phase Ib/II study of multiple treatment (tx) combinations in pts with locally advanced/metastatic BC (LA/mBC). ESMO Open. 9. 103203–103203. 16 indexed citations

12.

Reinisch, Mattea, Oleg Gluz, Beyhan Ataseven, et al.. (2023). Prognostic and predictive impact of gene expression in node‐positive early breast cancer patients receiving dose‐dense versus standard‐dose adjuvant chemotherapy. Molecular Oncology. 17(6). 1060–1075.

13.

Laurentiis, Michelino De, Luís Costa, Joseph Gligorov, et al.. (2022). EPIK-B5: A phase III, randomized study of alpelisib (ALP) plus fulvestrant (FUL) in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) progressing on/after an aromatase inhibitor (AI) with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i).. Journal of Clinical Oncology. 40(16_suppl). TPS1109–TPS1109. 7 indexed citations

14.

Schmid, Peter, Zbigniew Nowecki, Seock‐Ah Im, et al.. (2022). Abstract PD10-03: BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC): Results from Arm 1 D + paclitaxel (P), Arm 2 D+P + capivasertib (C), and Arm 5 D+P + oleclumab (O). Cancer Research. 82(4_Supplement). PD10–3. 3 indexed citations

15.

Rugo, Hope S., Aditya Bardia, Frederik Marmé, et al.. (2022). Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) advanced breast cancer.. Journal of Clinical Oncology. 40(17_suppl). LBA1001–LBA1001. 81 indexed citations

16.

Schmid‐Araya, J. M., et al.. (2016). Trophic positioning of meiofauna revealed by stable isotopes and food web analyses. Ecology. 97(11). 3099–3109. 25 indexed citations

17.

Schmid, Peter. (2010). Scale-dependent relations between bacteria, organic matter and invertebrates in a headwater stream. Fundamental and Applied Limnology / Archiv für Hydrobiologie. 176(4). 365–375. 5 indexed citations

18.

Hildrew, Alan G., James H. Brown, Stuart Humphries, et al.. (2007). Body Size: The Structure and Function of Aquatic Ecosystems. Cambridge University Press eBooks. 133 indexed citations

19.

Schmid‐Araya, J. M., et al.. (2002). The Importance of Meiofauna in Food Webs: Evidence from an Acid Stream. Ecology. 83(5). 1271–1271. 13 indexed citations

20.

Schmid, Peter. (1992). Population dynamics and resource utilization by larval Chironomidae (Diptera) in a backwater area of the River Danube. Freshwater Biology. 28(1). 111–127. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact